Discovery - University of Dundee - Online Publications

Library & Learning Centre

Proteinuria with fumaric acid ester treatment for psoriasis

Standard

Proteinuria with fumaric acid ester treatment for psoriasis. / Ogilvie, S.; Lewis Jones, S.; Dawe, R.; Foerster, J.

In: Clinical and Experimental Dermatology, Vol. 36, No. 6, 08.2011, p. 632-634.

Research output: Contribution to journalArticle

Harvard

Ogilvie, S, Lewis Jones, S, Dawe, R & Foerster, J 2011, 'Proteinuria with fumaric acid ester treatment for psoriasis' Clinical and Experimental Dermatology, vol 36, no. 6, pp. 632-634.

APA

Ogilvie, S., Lewis Jones, S., Dawe, R., & Foerster, J. (2011). Proteinuria with fumaric acid ester treatment for psoriasis. Clinical and Experimental Dermatology, 36(6), 632-634doi: 10.1111/j.1365-2230.2011.04047.x

Vancouver

Ogilvie S, Lewis Jones S, Dawe R, Foerster J. Proteinuria with fumaric acid ester treatment for psoriasis. Clinical and Experimental Dermatology. 2011 Aug;36(6):632-634.

Author

Ogilvie, S.; Lewis Jones, S.; Dawe, R.; Foerster, J. / Proteinuria with fumaric acid ester treatment for psoriasis.

In: Clinical and Experimental Dermatology, Vol. 36, No. 6, 08.2011, p. 632-634.

Research output: Contribution to journalArticle

Bibtex - Download

@article{50d643590e194ba485c03495e50b519c,
title = "Proteinuria with fumaric acid ester treatment for psoriasis",
author = "S. Ogilvie and {Lewis Jones}, S. and R. Dawe and J. Foerster",
year = "2011",
volume = "36",
number = "6",
pages = "632--634",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Proteinuria with fumaric acid ester treatment for psoriasis

A1 - Ogilvie,S.

A1 - Lewis Jones,S.

A1 - Dawe,R.

A1 - Foerster,J.

AU - Ogilvie,S.

AU - Lewis Jones,S.

AU - Dawe,R.

AU - Foerster,J.

PY - 2011/8

Y1 - 2011/8

N2 - <p>Fumaric acid esters (FAE) have been used in the treatment of psoriasis for many years. In general, they are regarded as relatively safe compared with other antipsoriatic systemic treatments, with the most notable adverse effects being gastrointestinal upset, lymphopenia and transient flushing. Renal toxicity has only rarely been reported, and was not found in two independent prospective trials nor in a large retrospective evaluation of almost 1000 patients treated for a median of 44 months. We report three patients developing reversible proteinuria during FAE treatment. One of these displayed the same pattern upon repeated drug administration, thereby clearly indicating FAE treatment to be the causal trigger. The presented cases highlight proteinuria as a clinical concern in FAE treatment. Furthermore, as the novel FAE agent dimethylfumaric (DMF) ester (contained in BG00012/Panaclar) has previously been shown to be effective in psoriasis in a phase III trial and not shown renal toxicity in a large trial for multiple sclerosis, the current report suggests that market introduction of DMF for psoriasis should be pursued.</p>

AB - <p>Fumaric acid esters (FAE) have been used in the treatment of psoriasis for many years. In general, they are regarded as relatively safe compared with other antipsoriatic systemic treatments, with the most notable adverse effects being gastrointestinal upset, lymphopenia and transient flushing. Renal toxicity has only rarely been reported, and was not found in two independent prospective trials nor in a large retrospective evaluation of almost 1000 patients treated for a median of 44 months. We report three patients developing reversible proteinuria during FAE treatment. One of these displayed the same pattern upon repeated drug administration, thereby clearly indicating FAE treatment to be the causal trigger. The presented cases highlight proteinuria as a clinical concern in FAE treatment. Furthermore, as the novel FAE agent dimethylfumaric (DMF) ester (contained in BG00012/Panaclar) has previously been shown to be effective in psoriasis in a phase III trial and not shown renal toxicity in a large trial for multiple sclerosis, the current report suggests that market introduction of DMF for psoriasis should be pursued.</p>

KW - ACUTE-RENAL-FAILURE

KW - LONG-TERM TREATMENT

KW - DOUBLE-BLIND

KW - MULTICENTER

KW - EFFICACY

KW - DERIVATIVES

KW - SAFETY

U2 - 10.1111/j.1365-2230.2011.04047.x

DO - 10.1111/j.1365-2230.2011.04047.x

M1 - Article

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 6

VL - 36

SP - 632

EP - 634

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy